CompletedNot Applicable

Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females

Brazil17 participantsStarted 2009-10

Plain-language summary

Orlistat is a popular drug approved for long-term use which produces weight loss by inhibiting triglycerides, main components of fats in the diet and reducing dietary fat absorption by up to 30%. The effect of this drug on human blood fatty acid profile has not been described yet. The FA composition of RBCs, plasma and platelets can be used to monitor of many pathological processes. This study presents alteration of FA composition in RBCM and phospholipids, triglycerides and cholesteryl esters from plasma of health obese female volunteers treated with nutritional orientation and orlistat (120 mg t.i.d) for 3 months.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Obesity BMC (Body Mass Index) between 30 to 40 kg/m2 Women 18 to 45 years Premenopausal stage Exclusion Criteria: * Relevant diseases (diabetes, cardiovascular, gastrointestinal, renal and hepatic diseases, endocrine disorders, hemoglobinopatHy or neoplasm in the last three years) * Chemical or natural laxatives * Weight variation greater than 5% in the preceding 3 months * Surgery for weight reduction * Drugs to obesity control and/or oral corticosteroids anti-inflammatory in the last three months

What they're measuring

Orlistat induced modulation on the Fatty Acid composition in Obese Females

Timeframe: baseline

Trial details

NCT IDNCT01414465

SponsorUniversity of Campinas, Brazil

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-03

View on ClinicalTrials.gov More Overweight trials